AnitaKumarMD

Hematologic Oncology

Associate Attending, Lymphoma Service, Memorial Sloan Kettering Cancer Center

Overview of Dr. Kumar

Dr. Anita Kumar is an oncologist in Basking Ridge, NJ and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Morristown Medical Center, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from McGaw Medical Center of Northwestern University and has been in practice 9 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 77 doctors at Morristown Medical Center who specialize in Oncology. She has more than 30 publications and over 300 citings.

Office
136 Mountain View Boulevard
Basking Ridge, NJ 07920
Book by Phone+1(316) 854-4075

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Northwestern University The Feinberg School of MedicineClass of 2008
Harvard CollegeBA, Biochemical Sciences, Cum Laude, 1999 - 2004

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2011 - 2026
NJ State Medical License 2018 - 2025
PA State Medical License 2023 - 2024
MA State Medical License 2010 - 2011

Clinical Trials

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma Start of enrollment: 2015 Jan 01
Completed
Phase 1
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Start of enrollment: 2017 Sep 20
Completed
Early Phase 1
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Start of enrollment: 2023 Mar 14
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Start of enrollment: 2024 Jan 08
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-08-01
1 citations
MYC overexpression: adding another piece to the puzzle of high-risk mantle cell lymphoma.
Anita Kumar
Haematologica. 2024-04-01
1 citations
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-04-01

Abstracts/Posters

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
Anita Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
Anita Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
Anita Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
Anita Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Anita Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Anita Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
Anita Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Azar Faulted Workers’ ‘Home and Social’ Situations for Meatpacking OutbreaksMay 7th, 2020